ChemicalBook > CAS DataBase List > Bevacizumab

Bevacizumab

Product Name
Bevacizumab
CAS No.
216974-75-3
Chemical Name
Bevacizumab
Synonyms
Avastin;Avastatin;Bevacizumab;Rhumab-vegf;Bevacituzumab;Unii-2S9zzm9Q9v;Bevacizumab Impurity;Bevacizumab (Avastin);Bevacizumab USP/EP/BP;BevacizuMab [USAN:INN]
CBNumber
CB3966244
Molecular Formula
C6638H10160N1720O2108S44
Formula Weight
0
MOL File
Mol file
More
Less

Bevacizumab Property

storage temp. 
Store at -80°C
solubility 
Soluble in DMSO
form 
Liquid
color 
Colorless to light yellow
More
Less

Safety

Hazardous Substances Data
216974-75-3(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
1445547
Product name
USP mAb 002, Monoclonal IgG1
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
2MG
Price
$1370
Updated
2024/03/01
Biosynth Carbosynth
Product number
FB76708
Product name
Bevacizumab - 25mg/ml solution in PBS
Packaging
25mg
Price
$1875
Updated
2021/12/16
ChemScene
Product number
CS-7820
Product name
Bevacizumab
Purity
≥99.0%
Packaging
25mg
Price
$2500
Updated
2021/12/16
ChemScene
Product number
CS-7820
Product name
Bevacizumab
Purity
≥99.0%
Packaging
50mg
Price
$4000
Updated
2021/12/16
Biosynth Carbosynth
Product number
FB76708
Product name
Bevacizumab - 25mg/ml solution in PBS
Packaging
1mg
Price
$150
Updated
2021/12/16
More
Less

Bevacizumab Chemical Properties,Usage,Production

Description

Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (Kd=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m2 i.v., 5-fluorouracil 500 mg/ m2 i.v., and leucovorin 20 mg/m2 i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.

Originator

Genentech (US)

brand name

Avastin

Clinical Use

Monoclonal antibody:

Treatment of colorectal cancer

Treatment of breast cancer

Treatment of renal cell carcinoma

Treatment of lung cancer

Treatment of ovarian, fallopian tube or peritoneal cancer

Enzyme inhibitor

This humanized monoclonal antibody (MW = 149.2 kDa; CAS 216974-75- 3), known by the tradename Avastinò, is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A). Because VEGF is the key angiogenic factor in tumors, blocking VEGF signal transduction can lead to tumor growth arrest and inhibition of metastasis. The rationale for Avastin therapy is premised on findings that high VEGF expression correlates with (a) reduced overall survival, (b) disease progression, (c) greater risk of relapse, (d) lymph node involvement, and (e) malignant pleural effusion. By binding directly bind to VEGF-A, Avastin blocks its interaction with endothelial cell VEGF receptors, thereby inhibiting neovascularization and depriving cancer cells of vital nutrients and oxygen. Avastin is approved for: metastatic colorectal cancer (mCRC), when started with the first or second intravenous 5-FU–based chemotherapy for metastatic cancer; advanced-stage nonsquamous, non–small cell lung cancer (NSCLC), when administered in combination with carboplatin and paclitaxel in patients who have not received chemotherapy for their advanced disease; metastatic renal cell cancer (mRCC) when used with interferon-a; and glioblastoma multiforme (GBM) in adult patients whose cancer has progressed after prior treatment.

target

Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents.  Bevacizumab is a humanised recombinant antibody that prevents vascular  endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth.

Drug interactions

Potentially hazardous interactions with other drugs
Bisphosphonates: increased risk of osteonecrosis of the jaw.
Cytotoxics: avoid with panitumumab.
Vaccines: risk of generalised infections with live vaccines - avoid.

Metabolism

Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.

Bevacizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Bevacizumab Suppliers

Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
+86-18521732826
Email
market@aladdin-e.com
Country
China
ProdList
48461
Advantage
58
Hefei Hirisun Pharmatech Co., Ltd.
Tel
+86-0551-62678551 +86-15056975894
Fax
0551-62678551
Email
sales@hirisunpharm.com
Country
China
ProdList
182
Advantage
55
Taizhou KEDE Chemical Co., Ltd
Tel
0576-84613060 13093829633
Fax
0576-84613060
Email
sales@kedechemical.com
Country
China
ProdList
298
Advantage
60
Hubei Zhongshan Medical Technology Co., Ltd
Tel
027-61907345 13397111514
Fax
3443707954
Email
w13397111514@163.com
Country
China
ProdList
1011
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59102966 18717199209
Fax
027-59379337
Email
2853877583@qq.com
Country
China
ProdList
2829
Advantage
58
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
19172
Advantage
64
Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Fax
+86 (27) 8331-4682
Email
whsrtech@vip.163.com
Country
China
ProdList
218
Advantage
62
Hunan Hui Bai Shi Biotechnology Co., Ltd.
Tel
0731-85526065 13308475853
Email
ivy@hnhbsj.com
Country
China
ProdList
4552
Advantage
62
More
Less

View Lastest Price from Bevacizumab manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Bevacizumab 216974-75-3
Price
US $0.00/G
Min. Order
1G
Purity
98%min
Supply Ability
30kg/month
Release date
2023-02-06
Hangzhou Huarong Pharm Co., Ltd.
Product
Bevacizumab 216974-75-3
Price
US $0.00-0.00/mg
Min. Order
1mg
Purity
99%
Supply Ability
100KG
Release date
2021-09-15

216974-75-3, BevacizumabRelated Search:


  • Avastin
  • BevacizuMab [USAN:INN]
  • Anti-vegf monoclonal antibody
  • Bevacizumab
  • Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-mouse monoclonal rhumab-vegf gamma1-chain), disulfide with human-mouse monoclonal rhumab-vegf light chain, dimer
  • Rhumab-vegf
  • Unii-2S9zzm9Q9v
  • Avastatin
  • Bevacituzumab
  • Bevacizumab (Avastin)
  • Bevacizumab - 25mg/ml solution in PBS
  • Bevacizumab(anti-VEGF)
  • Bevacizumab USP/EP/BP
  • Research Grade Bevacizumab(DHD12602)
  • Bevacizumab, Lyophilized powder
  • USP mAb 002, Monoclonal IgG1 (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED)
  • Bevacizumab Impurity
  • 216974-75-3
  • C6638H10160N1720O2108S44